Beijing Beilu Pharmaceutical Working Capital to Net Assets Ratio
Beijing Beilu Pharmaceutical working capital to net assets ratio. Beijing Beilu Pharmaceutical (300016) has a Working Capital to Net Assets ratio of 31.1% as of September 2025. Working capital of CN¥736.08 Million (current assets of CN¥1.34 Billion minus current liabilities of CN¥603.04 Million) is measured against net assets of CN¥2.37 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Beijing Beilu Pharmaceutical (2005–2024)
Working capital to net assets ratio of Beijing Beilu Pharmaceutical from 2005 to 2024. This chart shows how Beijing Beilu Pharmaceutical's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the ratio stands at 31.1%, reflecting working capital of CN¥736.08 Million against net assets of CN¥2.37 Billion CNY. Explore Beijing Beilu Pharmaceutical long-term investment intensity to see how much of total assets are deployed in long-term investments.
Beijing Beilu Pharmaceutical Working Capital to Net Assets Ratio by Year (2005–2024)
Beijing Beilu Pharmaceutical working capital to net assets ratio by year from 2005 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Beijing Beilu Pharmaceutical balance sheet assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 39.1% | CN¥715.95 Million | CN¥1.83 Billion | CN¥1.17 Billion | CN¥455.23 Million | ▼ -7.8 pp |
| 2023 | 46.9% | CN¥837.62 Million | CN¥1.79 Billion | CN¥1.20 Billion | CN¥359.17 Million | ▲ +1.4 pp |
| 2022 | 45.5% | CN¥875.34 Million | CN¥1.92 Billion | CN¥1.18 Billion | CN¥302.67 Million | ▼ -3.4 pp |
| 2021 | 49.0% | CN¥1.02 Billion | CN¥2.08 Billion | CN¥1.31 Billion | CN¥285.56 Million | ▼ -4.3 pp |
| 2020 | 53.2% | CN¥1.01 Billion | CN¥1.89 Billion | CN¥1.35 Billion | CN¥343.54 Million | ▲ +23.9 pp |
| 2019 | 29.3% | CN¥425.00 Million | CN¥1.45 Billion | CN¥550.89 Million | CN¥125.89 Million | ▼ -2.4 pp |
| 2018 | 31.7% | CN¥382.03 Million | CN¥1.21 Billion | CN¥444.17 Million | CN¥62.14 Million | ▼ -7.8 pp |
| 2017 | 39.5% | CN¥422.13 Million | CN¥1.07 Billion | CN¥471.35 Million | CN¥49.22 Million | ▼ -1.3 pp |
| 2016 | 40.8% | CN¥367.60 Million | CN¥901.69 Million | CN¥397.00 Million | CN¥29.40 Million | ▼ -9.6 pp |
| 2015 | 50.4% | CN¥469.84 Million | CN¥932.63 Million | CN¥547.98 Million | CN¥78.15 Million | ▲ +17.6 pp |
| 2014 | 32.8% | CN¥218.26 Million | CN¥666.33 Million | CN¥403.96 Million | CN¥185.70 Million | ▼ -36.4 pp |
| 2013 | 69.1% | CN¥386.72 Million | CN¥559.38 Million | CN¥415.51 Million | CN¥28.79 Million | ▼ -2.5 pp |
| 2012 | 71.7% | CN¥375.50 Million | CN¥523.96 Million | CN¥401.93 Million | CN¥26.44 Million | ▼ -9.2 pp |
| 2011 | 80.9% | CN¥397.40 Million | CN¥491.47 Million | CN¥416.35 Million | CN¥18.95 Million | ▲ +0.6 pp |
| 2010 | 80.3% | CN¥375.39 Million | CN¥467.62 Million | CN¥382.87 Million | CN¥7.49 Million | ▼ -9.8 pp |
| 2009 | 90.1% | CN¥390.60 Million | CN¥433.71 Million | CN¥408.21 Million | CN¥17.60 Million | ▲ +23.6 pp |
| 2008 | 66.4% | CN¥88.49 Million | CN¥133.23 Million | CN¥115.00 Million | CN¥26.52 Million | ▲ +17.0 pp |
| 2007 | 49.4% | CN¥44.60 Million | CN¥90.33 Million | CN¥94.25 Million | CN¥49.66 Million | ▲ +18.5 pp |
| 2006 | 30.8% | CN¥22.06 Million | CN¥71.59 Million | CN¥74.46 Million | CN¥52.40 Million | ▲ +13.2 pp |
| 2005 | 17.6% | CN¥11.40 Million | CN¥64.71 Million | CN¥52.45 Million | CN¥41.05 Million | — |